Note: This is an archived Handbook entry from 2014.
|Dates & Locations:|| |
This subject is not offered in 2014.
|Time Commitment:||Contact Hours: 3 x one hour lectures per week. Workshops will be held in lecture slots (total contact hours: 36) |
Total Time Commitment:
Study Period Commencement:
Study Period Commencement:
Students wishing to undertake this subject as breadth will need the approval of the subject co-ordinator.
|Recommended Background Knowledge:|| |
|Non Allowed Subjects:|| |
This subject cannot be taken if credit has been previously obtained for 534-304 Pharmacology of Therapeutic Substances.
|Core Participation Requirements:||
For the purposes of considering request for Reasonable Adjustments under the Disability Standards for Education (Cwth 2005), and Student Support and Engagement Policy, academic requirements for this subject are articulated in the Subject Overview, Learning Outcomes, Assessment and Generic Skills sections of this entry.
It is University policy to take all reasonable steps to minimise the impact of disability upon academic study, and reasonable adjustments will be made to enhance a student's participation in the University's programs. Students who feel their disability may impact on meeting the requirements of this subject are encouraged to discuss this matter with a Faculty Student Adviser and Student Equity and Disability Support: http://services.unimelb.edu.au/disability
Assoc Prof Richard Anthony Hughes
Assoc Prof Christine Wright:
Ms Hong Nguyen
Cancer, disorders of the immune system, cardiovascular diseases and acute and chronic lung disorders are the most common types of afflictions affecting people worldwide. This subject will examine the medicines that have been developed, or are currently being researched, to treat these diverse conditions.
This subject will present the scientific basis of present and likely future treatments of cancer, allergy, acute and chronic inflammation, infection, autoimmunity and transplant rejection, as well as of hypertension, heart failure, cardiovascular atheromatous disease and metabolic syndrome.
You will examine current knowledge of the pathogenesis of these disorders and the mechanisms of action of the major classes of drugs used to treat immune disorders, cancer, cardiovascular and respiratory diseases will be considered in the context of these systems and processes. The importance of biotechnology to these therapeutic areas will also be considered.
|Breadth Options:|| |
This subject potentially can be taken as a breadth subject component for the following courses:
You should visit learn more about breadth subjects and read the breadth requirements for your degree, and should discuss your choice with your student adviser, before deciding on your subjects.
|Fees Information:||Subject EFTSL, Level, Discipline & Census Date|
By the end of this unit students will:
This subject is available to students enrolled in the BSc, Biomedicine degree.
Biomedical Biotechnology (specialisation of Biotechnology major) |
Science credit subjects* for pre-2008 BSc, BASc and combined degree science courses
Science-credited subjects - new generation B-SCI and B-ENG.
Selective subjects for B-BMED
Download PDF version.